國立虎尾科技大學 |

Idiopathic pulmonary fibrosis = advances in diagnostic tools and disease management /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Idiopathic pulmonary fibrosis/ edited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
其他題名:	advances in diagnostic tools and disease management /
其他作者:	Nakamura, Hiroyuki.
出版者:	Tokyo :Springer Japan : : 2016.,
面頁冊數:	x, 259 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Pulmonary fibrosis. -
電子資源:	http://dx.doi.org/10.1007/978-4-431-55582-7
ISBN:	9784431555827

Idiopathic pulmonary fibrosis = advances in diagnostic tools and disease management /
Idiopathic pulmonary fibrosisadvances in diagnostic tools and disease management /[electronic resource] :edited by Hiroyuki Nakamura, Kazutetsu Aoshiba. - Tokyo :Springer Japan :2016. - x, 259 p. :ill., digital ;24 cm.

From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF) A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IP sufferers develop lung cancer.

ISBN: 9784431555827

Standard No.: 10.1007/978-4-431-55582-7doiSubjects--Topical Terms:

1021497
Pulmonary fibrosis.

LC Class. No.: RC776.F5

Dewey Class. No.: 616.24

Idiopathic pulmonary fibrosis = advances in diagnostic tools and disease management /
LDR:02168nam a2200301 a 4500 001 861109
003 DE-He213
005 20160727151452.0
006 m d
007 cr nn 008maaau
008 170720s2016 ja s 0 eng d
020 $a 9784431555827 $q (electronic bk.)
020 $a 9784431555810 $q (paper)
024 7 $a 10.1007/978-4-431-55582-7 $2 doi
035 $a 978-4-431-55582-7
040 $a GP $c GP
041 0 $a eng
050 4 $a RC776.F5
072 7 $a MJL $2 bicssc
072 7 $a MED079000 $2 bisacsh
082 0 4 $a 616.24 $2 23
090 $a RC776.F5 $b I19 2016
245 0 0 $a Idiopathic pulmonary fibrosis $h [electronic resource] : $b advances in diagnostic tools and disease management / $c edited by Hiroyuki Nakamura, Kazutetsu Aoshiba.
260 $a Tokyo : $c 2016. $b Springer Japan : $b Imprint: Springer,
300 $a x, 259 p. : $b ill., digital ; $c 24 cm.
520 $a From epidemiology and pathogenesis to disease management, this book reviews our current understanding of and provides up-to-date information of Idiopathic Pulmonary Fibrosis (IPF) A subtype of Idiopathic Interstitial Pneumonias (IIP), IPF is one of the most elusive and intractable respiratory disease to date and its triggering factors remain unclear. However, new developments such as serum markers that are highly specific to IPF (i.e. KL-6, SP-A, and SP-D), the establishment of systematic diagnostic imaging (HRCT) and accumulated reports of treatment using an antifibrotic agent (pirfenidone) are slowly improving our understanding of the disease. Edited by an established authority in the field and written by experts, this book will be valuable to not only to beginning learners but also to physicians, instructors and researchers whose work involves IIPs. With each chapter exploring critical questions, with unresolved issues and future prospects, the book offers a valuable resource for understanding issues such as the newly proposed entity of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema: CPFE) and the mechanism of how so many IP sufferers develop lung cancer.
650 0 $a Pulmonary fibrosis. $3 1021497
650 1 4 $a Medicine & Public Health. $3 593949
650 2 4 $a Pneumology/Respiratory System. $3 668561
650 2 4 $a Cytokines and Growth Factors. $3 787581
700 1 $a Nakamura, Hiroyuki. $3 1103255
700 1 $a Aoshiba, Kazutetsu. $3 1103256
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-4-431-55582-7
950 $a Medicine (Springer-11650)